Man Group
RPRX icon

Man Group’s Royalty Pharma RPRX Stock Holding History

Man Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.34M Sell
166,593
-235,432
-59% -$12.3M 0.01% 830
2026
Q1 		$19.3M Buy
402,025
+13,863
+4% +$607K 0.04% 515
2025
Q4 		$15M Buy
388,162
+201,080
+107% +$7.67M 0.03% 625
2025
Q3 		$6.6M Buy
187,082
+172,844
+1,214% +$6.26M 0.01% 966
2025
Q2 		$513K Sell
14,238
-64,673
-82% -$2.14M ﹤0.01% 1825
2025
Q1 		$2.46M Sell
78,911
-736,516
-90% -$23.3M 0.01% 1285
2024
Q4 		$20.8M Buy
815,427
+433,245
+113% +$11.5M 0.05% 413
2024
Q3 		$10.8M Sell
382,182
-628,286
-62% -$17.4M 0.03% 707
2024
Q2 		$26.6M Buy
1,010,468
+813,343
+413% +$22.5M 0.07% 346
2024
Q1 		$5.99M Sell
197,125
-2,382,027
-92% -$70.2M 0.02% 928
2023
Q4 		$72.4M Buy
+2,579,152
New +$70.9M 0.2% 107
2023
Q3 		– Sell
-578,053
Closed -$17.2M – 249
2023
Q2 		$17.8M Buy
+578,053
New +$19.6M 0.05% 419
2023
Q1 		– Sell
-321,558
Closed -$11.9M – 517
2022
Q4 		$12.7M Buy
321,558
+18,465
+6% +$771K 0.05% 478
2022
Q3 		$12.2M Buy
+303,093
New +$12.9M 0.06% 413
2022
Q2 		– Sell
-176,115
Closed -$7.22M – 371
2022
Q1 		$6.86M Buy
176,115
+135,259
+331% +$5.31M 0.02% 761
2021
Q4 		$1.63M Buy
+40,856
New +$1.59M 0.01% 1218
2021
Q2 		– Sell
-24,232
Closed -$1.06M – 2078
2021
Q1 		$1.06M Buy
+24,232
New +$1.15M ﹤0.01% 1279
2020
Q4 		– Sell
-37,062
Closed -$1.56M – 1920
2020
Q3 		$1.56M Buy
+37,062
New +$1.59M 0.01% 1265

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Man Group's RPRX Position: Q2 2026 in Review

Man Group reduced its Royalty Pharma (RPRX) stake by 59% in Q2 2026, selling an estimated $12.3M and leaving 166,593 shares worth $9.34M. The position accounts for 0.01% of the portfolio, ranked #830.

Man Group first reported a position in RPRX in Q3 2020 and has held it in 18 quarters since. The position peaked at $72.4M in Q4 2023. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Man Group held 166,593 shares of Royalty Pharma worth $9.34M as of Q2 2026.
  • Man Group sold 235,432 Royalty Pharma shares in Q2 2026, an estimated $12.3M.
  • Royalty Pharma made up 0.01% of Man Group's portfolio in Q2 2026, its #830 holding.
  • Man Group first reported a position in Royalty Pharma in Q3 2020 and has held it in 18 quarters since.
  • Man Group's Royalty Pharma position peaked at $72.4M in Q4 2023.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.